UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 30

Sortiert nach

Chromosome 1q21.3 amplification is a trackable biomarker and actionable target for breast cancer recurrence

Nature medicine, 2017-11, Vol.23 (11), p.1319-1330

2017

Volltextzugriff (PDF)

SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer

Breast cancer research : BCR, 2018-06, Vol.20 (1), p.60-60, Article 60

2018

Volltextzugriff (PDF)

Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: A case control study

Molecular oncology, 2014-07, Vol.8 (5), p.874-883

2014

Volltextzugriff (PDF)

Global microRNA expression profiling of high-risk ER+ breast cancers from patients receiving adjuvant tamoxifen mono-therapy: a DBCG study

PloS one, 2012-05, Vol.7 (5), p.e36170-e36170

2012

Volltextzugriff (PDF)

The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer

Breast cancer research and treatment, 2012-07, Vol.134 (1), p.207-217

2012

Volltextzugriff (PDF)

Identification of genes for normalization of real-time RT-PCR data in breast carcinomas

BMC cancer, 2008-01, Vol.8 (1), p.20-20, Article 20

2008

Volltextzugriff (PDF)

Gene expression signatures that predict outcome of tamoxifen-treated estrogen receptor-positive, high-risk, primary breast cancer patients: a DBCG study

PloS one, 2013-01, Vol.8 (1), p.e54078-e54078

2013

Volltextzugriff (PDF)

Decorin is down-regulated in multiple myeloma and MGUS bone marrow plasma and inhibits HGF-induced myeloma plasma cell viability and migration

European journal of haematology, 2013-09, Vol.91 (3), p.196-200

2013

Volltextzugriff (PDF)

CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial

JNCI : Journal of the National Cancer Institute, 2012-03, Vol.104 (6), p.441-451

2012

Volltextzugriff (PDF)

Coexisting genomic aberrations associated with lymph node metastasis in breast cancer

The Journal of clinical investigation, 2018-06, Vol.128 (6), p.2310-2324

2018

Volltextzugriff (PDF)

Association of tissue inhibitor of metalloproteinases-1 and Ki67 in estrogen receptor positive breast cancer

Acta oncologica, 2013-01, Vol.52 (1), p.82-90

2013

Volltextzugriff (PDF)

Prospective validation of a blood-based 9-miRNA profile for early detection of breast cancer in a cohort of women examined by clinical mammography

Molecular oncology, 2016-12, Vol.10 (10), p.1621-1626

2016

Volltextzugriff (PDF)

Integrative analysis of miRNA and gene expression reveals regulatory networks in tamoxifen-resistant breast cancer

Oncotarget, 2016-08, Vol.7 (35), p.57239-57253

2016

Volltextzugriff (PDF)

Expression of osteoblast and osteoclast regulatory genes in the bone marrow microenvironment in multiple myeloma: only up-regulation of Wnt inhibitors SFRP3 and DKK1 is associated with lytic bone disease

Leukemia & lymphoma, 2014-04, Vol.55 (4), p.911-919

2014

Volltextzugriff (PDF)

Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors

Breast cancer research : BCR, 2009-01, Vol.11 (1), p.R11-R11, Article R11

2009

Volltextzugriff (PDF)

CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1–98 trial

Breast cancer research and treatment, 2015-06, Vol.151 (2), p.373-384

2015

Volltextzugriff (PDF)

Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease

British journal of haematology, 2013-05, Vol.161 (3), p.373-382

2013

Volltextzugriff (PDF)

miR-155, identified as anti-metastatic by global miRNA profiling of a metastasis model, inhibits cancer cell extravasation and colonization in vivo and causes significant signaling alterations

Oncotarget, 2015-10, Vol.6 (30), p.29224-29239

2015

Volltextzugriff (PDF)

Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients

Breast cancer research and treatment, 2015-12, Vol.154 (3), p.483-494

2015

Volltextzugriff (PDF)

The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence

JAMA oncology, 2016-02, Vol.2 (2), p.217

2016

Volltextzugriff (PDF)

Intratumor genetic heterogeneity of breast carcinomas as determined by fine needle aspiration and TaqMan low density array

Analytical cellular pathology (Amsterdam), 2007, Vol.29 (5), p.361-372

2007

Volltextzugriff (PDF)

Evaluation of the ability of adjuvant tamoxifen-benefit gene signatures to predict outcome of hormone-naive estrogen receptor-positive breast cancer patients treated with tamoxifen in the advanced setting

Molecular oncology, 2014-12, Vol.8 (8), p.1679-1689

2014

Volltextzugriff (PDF)

Advantages of multiple clinical tests for determining the optimum treatment strategy for ER-positive breast cancer

Nature clinical practice. Oncology, 2008-07, Vol.5 (7), p.376-377

2008

Volltextzugriff (PDF)

Expression of Wnt-Inhibitors and SDF-1 in Whole Bone Marrow Biopsies in Association to the Osteolytic Bone Disease of Multiple Myeloma

Blood, 2012-11, Vol.120 (21), p.2922-2922

2012

Volltextzugriff (PDF)

Expression of Factors in the Hepatocyte Growth Factor (HGF) Pathway in Whole Bone Marrow Biopsies in Association to the Osteolytic Bone Disease of Multiple Myeloma

Blood, 2012-11, Vol.120 (21), p.3977-3977

2012

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(30)

Sprache

Englisch
(30)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

Science & Technology
(25)
Life Sciences & Biomedicine
(24)
Humans
(23)
Female
(21)
Breast Cancer
(18)
Oncology
(18)
Middle Aged
(15)
Aged
(13)
Breast Neoplasms - Genetics
(11)
Tumors
(11)
Breast Neoplasms - Drug Therapy
(9)
Breast Neoplasms - Pathology
(9)
Gene Expression
(9)
Breast Neoplasms - Metabolism
(8)
Gene Expression Profiling
(8)
Prognosis
(8)
Cancer Therapies
(7)
Gene Expression Regulation, Neoplastic
(7)
Health Aspects
(7)
Immunohistochemistry
(7)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Breast Cancer Research And Treatment
(4)
Molecular Oncology
(3)
Blood
(2)
Breast Cancer Research
(2)
Breast Cancer Research : Bcr
(2)
Oncotarget
(2)
Plos One
(2)
Acta Oncologica
(1)
Analytical Cellular Pathology
(1)
Bioresource Technology
(1)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Chromosome 1q21.3 amplification is a trackable biomarker and actionable target for breast cancer recurrence

SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer

Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: A case control study

Global microRNA expression profiling of high-risk ER+ breast cancers from patients receiving adjuvant tamoxifen mono-therapy: a DBCG study

The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer

Identification of genes for normalization of real-time RT-PCR data in breast carcinomas

Gene expression signatures that predict outcome of tamoxifen-treated estrogen receptor-positive, high-risk, primary breast cancer patients: a DBCG study

Decorin is down-regulated in multiple myeloma and MGUS bone marrow plasma and inhibits HGF-induced myeloma plasma cell viability and migration

CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial

Coexisting genomic aberrations associated with lymph node metastasis in breast cancer

Association of tissue inhibitor of metalloproteinases-1 and Ki67 in estrogen receptor positive breast cancer

Prospective validation of a blood-based 9-miRNA profile for early detection of breast cancer in a cohort of women examined by clinical mammography

Integrative analysis of miRNA and gene expression reveals regulatory networks in tamoxifen-resistant breast cancer

Expression of osteoblast and osteoclast regulatory genes in the bone marrow microenvironment in multiple myeloma: only up-regulation of Wnt inhibitors SFRP3 and DKK1 is associated with lytic bone disease

Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors

CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1–98 trial

Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease

miR-155, identified as anti-metastatic by global miRNA profiling of a metastasis model, inhibits cancer cell extravasation and colonization in vivo and causes significant signaling alterations

Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients

The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence

Intratumor genetic heterogeneity of breast carcinomas as determined by fine needle aspiration and TaqMan low density array

Evaluation of the ability of adjuvant tamoxifen-benefit gene signatures to predict outcome of hormone-naive estrogen receptor-positive breast cancer patients treated with tamoxifen in the advanced setting

Advantages of multiple clinical tests for determining the optimum treatment strategy for ER-positive breast cancer

Expression of Wnt-Inhibitors and SDF-1 in Whole Bone Marrow Biopsies in Association to the Osteolytic Bone Disease of Multiple Myeloma

Expression of Factors in the Hepatocyte Growth Factor (HGF) Pathway in Whole Bone Marrow Biopsies in Association to the Osteolytic Bone Disease of Multiple Myeloma

Suchergebnisse filtern